No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Investing

Elon Musk to scale back White House advisory role and refocus on business interests

by
April 2, 2025
in Investing
0
Elon Musk to scale back White House advisory role and refocus on business interests
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Billionaire entrepreneur Elon Musk is set to step back from his advisory role within the Trump administration, according to reports from Politico.

US President Donald Trump is said to have informed close aides that Musk will return his attention to his business ventures in the coming weeks, having overseen what has been described as an “unprecedented programme” of government cost-cutting during his time advising the White House.

Despite recent speculation about tensions behind the scenes, Trump is understood to remain satisfied with Musk’s contributions, crediting the Tesla and SpaceX chief executive with helping to drive significant budgetary efficiencies.

However, Politico reports growing concern among senior officials that Musk, 53, had begun to overstep his advisory remit, leading to his influence becoming more of a liability than an asset.

While no formal statement has yet been made by either Musk or the White House, sources suggest the transition has been agreed internally, allowing Musk to refocus on his portfolio of technology and infrastructure ventures — including Tesla, SpaceX, X (formerly Twitter), and xAI.

The move marks a shift in Musk’s recent visibility in Washington, where he had become a high-profile voice in discussions around federal spending, regulation, and public sector innovation.

Industry watchers will now be paying close attention to how the tech mogul balances his ongoing business ambitions with his evident interest in influencing policy — particularly as the 2024 US election cycle gathers momentum.

Read more:
Elon Musk to scale back White House advisory role and refocus on business interests

Previous Post

Hilary Jackson’s Journey from Riding Alone to Finding a Common Cause: A Bike the UK for MS Experience

Next Post

UK economic forecasts called into question as ONS data reliability falters

Next Post
UK economic forecasts called into question as ONS data reliability falters

UK economic forecasts called into question as ONS data reliability falters

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024
Idaho Bucks Managed Care Trend

Idaho Bucks Managed Care Trend

December 5, 2023

Last Day to Give in 2023!

December 31, 2023

The Producer Price Index

September 9, 2023

Is Culture Degeneration Biological or Ideological?

0

0

0

0

Is Culture Degeneration Biological or Ideological?

May 24, 2025

Price Controls and Drug Shortages in France: A Textbook Case of the Evils of Interventionism

May 24, 2025

Is Culture Degeneration Biological or Ideological?

May 24, 2025

Price Controls and Drug Shortages in France: A Textbook Case of the Evils of Interventionism

May 24, 2025

Recent News

Is Culture Degeneration Biological or Ideological?

May 24, 2025

Price Controls and Drug Shortages in France: A Textbook Case of the Evils of Interventionism

May 24, 2025

Is Culture Degeneration Biological or Ideological?

May 24, 2025

Price Controls and Drug Shortages in France: A Textbook Case of the Evils of Interventionism

May 24, 2025

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.